Gossamer Bio (GOSS) Non-Current Deffered Revenue (2024 - 2026)

Gossamer Bio's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $31.9 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 13.08% year-over-year to $31.9 million; the TTM figure through Mar 2026 stood at $31.9 million (down 13.08% YoY), while the FY2025 annual figure was $29.6 million, down 23.83% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $31.9 million, up from $29.6 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $49.7 million in Q2 2024, with the low at $27.1 million in Q3 2025.
• The 3-year median for Non-Current Deffered Revenue is $34.3 million (2025), against an average of $36.1 million.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue sank 38.18% in 2025, then dropped 13.08% in 2026.
• Gossamer Bio's Non-Current Deffered Revenue stood at $38.9 million in 2024, then dropped by 23.83% to $29.6 million in 2025, then advanced by 7.75% to $31.9 million in 2026.
• Business Quant data shows GOSS's Non-Current Deffered Revenue at $31.9 million in Q1 2026, $29.6 million in Q4 2025, and $27.1 million in Q3 2025.